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INTRODUCTION
Ghelardini et al. (27) reported that atropine at very low doses induces central antinoci-
ception in rodents through an enhancement of cholinergic transmission. Soon after, it was
discovered that the R-(+)-enantiomer of atropine, R-(+)-hyoscyamine, was responsible for
the antinociceptive activity of the racemate, while the S-(–)-enantiomer, S-(–)-hyoscy-
amine, was devoid of any antinociceptive action (29). R-(+)-hyoscyamine, in the same
range of analgesic doses, was also able to prevent amnesia induced by antimuscarinic
drugs (35). It is interesting to note that this antinociceptive activity, different from that
produced by direct muscarinic agonists and cholinesterase inhibitors, was not accom-
panied by typical cholinergic symptoms (e.g., tremors, sialorrhea, diarrhea, rhinorrhea,
lacrimation). An investigation of the antinociceptive and antiamnesic effect of atropine
has demonstrated, using microdialysis techniques, that R-(+)-hyoscyamine, at cholinomi-
metic doses, produced an increase in acetylcholine (ACh) release from the rat cerebral
cortex in vivo, indicating that it acts via a presynaptic mechanism (35).
On this basis, a synthetic program to modify the chemical structure of atropine was
started, which aimed to develop cholinergic amplifiers endowed with more intensive anti-
nociceptive and antiamnesic activities than atropine but, like atropine, lacking cholinergic
side effects. These compounds would, therefore, be potentially useful as analgesics andor
in pathological conditions characterized by cholinergic deficits (e.g., Alzheimer’s
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disease). Of the many compounds synthesized and studied, -tropanyl 2-(4-bromophe-
nyl)propionate labeled PG-9 (45) (Fig. 1) showed an interesting pharmacological profile.
CHEMISTRY
The chemical structure of the lead compound, R-(+)-hyoscyamine, was extensively
manipulated in order to overcome the stability problems associated with tropic acid deriv-
atives and to obtain more efficacious antinociceptive compounds. The removal of the hy-
droxyl group to form -tropanyl 2-phenylpropionate (ET-103) (43) gave a compound 70-
times less potent but with similar efficacy as the lead compound (45). Better results were
obtained with the series of substituted 2-phenylpropionic acid esters; in fact, with the ap-
propriate substituent on the phenyl ring (4-Br, 4-F, 4-OMe, 2-, 3-, or 4-Cl) compounds
which showed lower potency than ET-103 but a much higher analgesic efficacy were ob-
tained (45). In this series, as well as in that of the 2-phenoxypropionic acid derivatives,
antinociceptive activity was limited to the -tropanyl ester (44). Among all compounds of
the series, -tropanyl 2-(4-bromophenylpropionate (PG-9) showed the best combination
of potency and efficacy and was selected for further studies. The synthetic pathway used
for its synthesis is shown in Fig. 1. Single enantiomers were synthesized and studied be-
cause PG-9 possesses a stereogenic center (68,39). They showed enantioselectivity in
pharmacological activity, although, unlike atropine enantiomers (35), both stereoisomers
of PG-9 had analgesic and nootropic properties. In any case, the most potent and effica-
cious stereoisomer (S-(+)-PG-9) possesses the same spatial arrangement at the chiral
center as the lead compound, R-(+)-hyoscyamine (68).
IN VIVO STUDIES
Antinociceptive Properties
PG-9 induced antinociception in mice and rats. Antinociception was elicited, re-
gardless of the noxious stimulus used: thermal (hot-plate and tail flick tests), chemical
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Fig. 1. Chemical structure and synthesis of PG-9.
(abdominal constriction test) or mechanical (paw pressure test). The methods used were
those of O’Callaghan and Holtzman (62), D’Amour and Smith (16), Koster et al. (53), and
Leighton et al. (56), respectively.
In the mice hot-plate test PG-9, by systemic administration (i.e., i.p., p.o., i.v.), pro-
duced a dose-dependent increase in the pain threshold (Fig. 2; ref. 37). A similar effect
was obtained with the abdominal constriction test in mice (Fig. 3, panel A). The maximal
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Fig. 2. Dose-response curves of PG-9 i.p. (a) and i.c.v. (c) in the mouse hot-plate test. The PG-9 time course of
40 mgkg i.p. is reported in b and 20 g per mouse i.c.v. in d from the same test. Vertical lines give 
 S.E.M..
Each point is the mean of at least 10 mice. ^P < 0.05; *P < 0.01 vs. controls. In a and c PG-9 was administered
15 min before the test.
antinociceptive effect of PG-9 was reached at 15 min after its administration. Thereafter,
the effect slowly diminished (Fig. 2, panels B and D). PG-9 also produced an increase in
CNS Drug Reviews, Vol. 6, No. 1, 2000
66 C. GHELARDINI ET AL.
Fig. 3. Antinociceptive effect of PG-9 and antagonism by hemicholinium-3 (HC-3) (1 g per mouse i.c.v.), at-
ropine (5 mgkg i.p.), and dicyclomine (10 mg per mouse i.p.) on the enhancement of pain threshold induced by
PG-9 (20 mgkg s.c.) in the mouse abdominal constriction test induced by 0.6% acetic acid (a) and in the rat
paw-pressure tests (b). HC-3, atropine or dicyclomine were injected, respectively, 5 h, 15 min and 10 min before
testing. In the abdominal constriction test the nociceptive responses were recorded 15 min after PG-9 adminis-
tration. Vertical lines show S.E.M. ^P < 0.05; *P < 0.01 vs. saline controls. °P < 0.01 vs. PG-9 (20 mgkg s.c.).
Numbers inside the columns indicate the number of mice or rats.
the pain threshold in rats (paw pressure: Fig. 3, panel B; tail flick: ref. 37) with a pharma-
cological profile similar to that in mice. Both PG-9 enantiomers dose-dependently in-
creased the pain threshold in mouse hot-plate and abdominal constriction test, although
R-(+)-PG-9 was slightly more effective than S-(–)-PG-9 (37,68).
PG-9 is endowed with central antinociceptive activity. It was, in fact, possible to reach
the same intensity of analgesia by injecting PG-9 directly into the cerebral ventricles by
methods previously described (46) at 10–30 g per mouse (Fig. 2, panel C; ref. 37). Its ac-
tivity at such low doses ruled out the possibility that the antinociception could have been
due to retrodiffusion of the drug from the cerebral ventricles to the periphery.
PG-9 showed good antinociceptive efficacy in comparison to R-(+)-hyoscyamine or
well known analgesic drugs, such as morphine, diphenhydramine, or clomipramine. As a
matter of fact, a comparison of the areas under the activity curves of the above-mentioned
compounds at the highest doses that do not impair normal behavior of mice revealed that
PG-9 was as effective as morphine and more effective than R-(+)-hyoscyamine, diphenhy-
dramine, or clomipramine (37).
At doses lower than 1 mgkg, PG-9 reduced the number of abdominal constrictions in-
duced by i.p. injection of 0.3% acetic acid and reversed hyperalgesia induced by morphine
withdrawal.
PG-9 antinociception is not due to an antiinflammatory action. At concentrations up to
10–4 molL PG-9 did not inhibit inducible COX activity, while indomethacin (IC50)
27  10–6 molL was effective. Furthermore, PG-9 failed to suppress carrageenan-induced
paw edema at analgesic doses (Table 1).
Antiamnesic Activity
PG-9 ameliorates impaired cognitive processes in mice. In the passive avoidance test
this compound prevented amnesia induced by scopolamine, dicyclomine (Fig. 4), or
(–)-ET-126 (36). Complete prevention of amnesia was obtained with PG-9 at 10 mgkg
i.p. (Fig. 4) or 20 g i.c.v. (36). At these doses PG-9 had only weak analgesic activity in
the hot-plate test. To prevent amnesia, PG-9 was administered at 20 min before the
training session, since the time-course of the antiamnesic activity of PG-9 indicates that
the compound reaches its maximal effect at 15–30 min after injection.
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TABLE 1. Effect of PG-9 on carrageenan-induced paw edema in rats
Pretreatment Treatment Dose (mgkg i.p.) Paw volume (ml 
 S.E.M.)
Saline Saline 1.25 
 0.08
Carrageenan Saline 2.31 
 0.06
Carrageenan PG-9 20 2.37 
 0.08
Carrageenan PG-9 40 2.39 
 0.10
Carrageenan Indomethacin 1 1.45 
 0.07*
Indomethacin was used as positive control; n = 5 rats per group. *P < 0.05 in comparison with
carrageenan-saline controls. PG-9 was injected 15 min before the test.
In the passive avoidance test, an improvement in cognition of animals with no memory
impairment is difficult to demonstrate. As a matter of fact, PG-9 as well as well-known
nootropic drugs, such as piracetam, aniracetam, and rolipram or cholinomimetics, such as
physostigmine and oxotremorine, do not show any memory facilitation in normal animals
(15,41). The procognitive activity of PG-9 was unmasked by using a social learning test,
which was performed according to methods described by Mondadori et al. (61). PG-9 ex-
erted beneficial effects on cognitive performance by prolonging the time normally re-
quired by rats to delete mnemonic information (data not shown).
Effect of PG-9 on Animal Behavior
PG-9 produced its maximal antinociceptive effect at 40 mgkg s.c. without any visible
modification in gross behavior of either mice or rats. Moreover, mice treated with the
same dose of PG-9 retained motor coordination in the rotating rod test (method of Kuri-
bara et al., 54) (Table 2). Under these experimental conditions, the effects of PG-9 were
compared to those of pilocarpine or physostigmine at equi-effective doses (Table 2). Both
the muscarinic agonist and the inhibitor of cholinesterase produced a statistically signif-
icant reduction in endurance time on the rotating rod. The spontaneous motility of mice,
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Fig. 4. Effect of PG-9 (i.p.), aniracetam (p.o.), and physostigmine (i.p.) on dicyclomine-induced amnesia in
mouse passive avoidance test and, under the same experimental conditions, effect of PG-9 on scopolamine am-
nesia. Punishment consists of a fall into cold water (10°C). PG-9, aniracetam, and physostigmine were injected
20 min before the training session. Scopolamine and dicyclomine were injected immediately after the training
session. *P < 0.01 vs. saline controls. Each column represents the mean of at least 25 mice.
evaluated by the Animex apparatus, as well as the exploratory behavior, studied by the
hole-board test (36), were normal after the administration of PG-9 at 40 mgkg s.c. or
30 g per mouse i.c.v. Impaired motor coordination and spontaneous motility were ob-
served in mice after PG-9 was administered alone at doses starting at 100 mgkg s.c.,
whereas its LD50 was 400 mgkg s.c.
Effect on Intestinal Motility
PG-9 did not modify intestinal transit time in mice at analgesic and antiamnesic doses
as determined by the technique of Reynell and Spray (67) (data not shown). In contrast,
other analgesic drugs, such as morphine, significantly retarded gastrointestinal propulsion,
whereas the cholinesterase inhibitor, neostigmine, accelerated net propulsion (72). The
lack of effect of PG-9 on intestinal motility indicates that this compound has the same
analgesic activity and may be superior to opioid analgesics, which produce constipation,
or to classical cholinomimetics, which cause diarrhea.
IN VITRO STUDIES
Effect on Endogenous Nerve Growth Factor
In vitro administration of PG-9 increased the secretion of Nerve Growth Factor (NGF)
by astrocytes in a dose-dependent manner (36). After addition of PG-9 the maximal NGF
levels were 17.6 time greater that the control value. In cultured astrocytes, effective con-
centrations of PG-9 produced no morphological changes. However, slight cell toxicity or
morphological changes were observed with PG-9 at 1 mgmL. (36). Cultured quiescent
astrocytes can be used to study the effects of drugs on NGF synthesis since NGF synthesis
is regulated in a growth-dependent manner in cultured astrocytes; most of the astrocytes in
the brain are in the quiescent phase and do not express the NGF gene with in vivo
administration.
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TABLE 2. Effect of PG-9 in comparison with pilocarpine and physostigmine in the rotarod test
Treatment s.c.
Endurance time on rotarod (sec)
Before
treatment
After treatment
15 min 30 min 45 min
Saline 104.3 
 6.2 (18) 106.7 
 6.0 (18) 107.8 
 5.9 (18) 103.5 
 6.2 (18)
PG-9 (40 mgkg) 101.2 
 5.9 (10) 96.7 
 8.2 (10) 95.6 
 9.4 (10) 106.2 
 8.4 (10)
Pilocarpine (10 mgkg) 108.2 
 8.4 (11) 66.5 
 7.1* (11) 61.3 
 9.6* (11) 74.4 
 8.7* (11)
Physostigmine (200 gkg) 93.4 
 5.7 (9) 61.4 
 6.8* (9) 54.4 
 8.1* (9) 52.3 
 8.8* (9)
*P < 0.05 vs. saline controls. The number of mice is shown in parentheses.
Effect on Isolated Guinea Pig Ileum
When added to the organ bath at concentrations ranging from 1 pmolL to 0.1 nmolL,
PG-9 potentiated contractions evoked by either nicotine (4 molL) or electrical stimu-
lation [0.1 Hz, 0.5 msec, voltage double threshold, method of Paton and Vizi (64)]
(Fig. 5). As measured by the area under the curve, PG-9 potentiated contractions induced
by nicotine to a greater extent than those induced by electrical stimulation. The
potentiation was no longer observed when the concentration of PG-9 in the medium
reached 0.1 nM. At 10 nmolL PG-9 began to inhibit both types of evoked contractions.
Nicotine-evoked contractions were about four times larger than those evoked electrically
(Fig. 5). The difference in the magnitude of contraction is probably due to the fact that
during electrically-evoked contractions both intramural cholinergic and sympathetic fibers
are activated, whereas only cholinergic fibers are activated during nicotine-evoked con-
tractions. Norepinephrine released during electrical stimulation is likely to limit the effect
of ACh released after the administration of low concentrations of PG-9. The greater
potentiation of the nicotine-evoked contractions compared to those elicited by electrical
stimulation can be explained by the inhibitory effect of norepinephrine, which is released
only during electrical stimulation (27).
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Fig. 5. Dose-response curves of PG-9 on nicotine (4 M) () and electrically (0.1 Hz; 0.5 msec; double
threshold voltage) evoked contractions () of guinea-pig ileum myenteric plexus longitudinal muscle strip ex-
pressed as percentage variation of contractions. Each point represents the mean of at least 6 experiments and ver-
tical lines give S.E.M. *P < 0.05 calculated in the range between 0.1 pM–0.1 nM.
Rat Phrenic Nerve-Hemidiaphragm Preparation
PG-9 (1 pmolL – 1 nmolL; > 1 molL) potentiated contractions of hemidiaphragm
evoked by electrical stimulation of the left phrenic nerve (Fig. 6, panel A). ACh release
(Fig. 6, panel B), studied by the method of Bülbring (9) as modified by Wessler and Kil-
binger (75), was also enhanced by PG-9, while contractions evoked by the direct stimu-
lation of the diaphragm were not modified by the drug. At concentration greater than
1 molL, numerous muscarinic antagonists, such as atropine, pirenzepine, dicyclomine,
or glycopyrrolate are known to enhance hemidiaphragm contractions by blocking musca-
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Fig. 6. Dose-response curves of PG-9: (a) on electrically evoked phrenic nerve-hemidiaphragm contractions
(0.2 Hz, 0.5 msec, twice threshold voltage); (b) on tritium efflux from the same preparation preloaded with
[3H]choline. Each point represents the mean of 6 experiments. Vertical lines give 
 S.E.M. *P < 0.05 calculated
in the range between 10–9–10–12 M.
rinic autoreceptors (66,76). The effects of high concentrations of PG-9, may, therefore, in-
volve an antagonism at muscarinic receptor subtypes. The potentiating effect of PG-9
(1 pmolL to 0.1 nmolL) on both parameters parallels the effect of R-(+)-hyoscyamine
under the same experimental conditions (33), although the underlying mechanism of PG-9
action should still be considered unknown. The inability to inhibit hemidiaphragm con-
tractions induced by electrical stimulation rules out the possibility that PG-9 may act as a
local anesthetic. Local anesthetics, such as lidocaine and procaine, dose-dependently in-
hibit the electrically-induced contractions of this preparation and abolish them at higher
concentrations (1). Also, unlike local anesthetics, PG-9 did not inhibit cutaneous muscle
reflex in guinea pig dorsal skin.
MECHANISM OF ACTION
The antinociceptive effect of PG-9 appears to depend on cholinergic activation since it
is antagonized by the muscarinic antagonist atropine (Fig. 3, panels A and B; ref. 37), the
M1 antagonists dicyclomine (Fig. 3, panels A and B) and pirenzepine (37), as well as by
the ACh depletor HC-3 (Fig. 3, panels A and B). Moreover, the antagonism of PG-9-in-
duced antinociception by i.c.v. injected HC-3 in mice (see Antinociceptive Properties
section), indicates that the site of action of PG-9 is central.
Microdialysis studies (method of Giovannini et al., 39) indicate that PG-9 increases
ACh release from the rat cerebral cortex; this effect peaked at 45–60 min after adminis-
tration of the drug, and the ACh levels returned to basal values within 120 min (Fig. 7).
PG-9 enhanced ACh release at the same dose range (10–20 mgkg, i.p.) that PG-9 exerts
its antinociceptive and antiamnesic activities. The latency for the maximal potentiation of
ACh release was longer than for drug activity, possibly because ACh may require time to
diffuse from the synaptic cleft to the microdialysis tube. The hypothesis that PG-9 acts via
a presynaptic cholinergic mechanism is supported by the following observations: PG-9
enhances ACh release and contractions of the rat hemidiaphragm preparation (Fig. 6);
PG-9 potentiates electrically and chemically evoked contractions of guinea pig ileum lon-
gitudinal muscle strips (Fig. 5) without modifying their basal tone; and the ACh depletor
HC-3 antagonizes PG-9-induced antinociception (Fig. 3).
A postsynaptic mechanism of action for PG-9 can be ruled out since, as reported by
Bartolini et al. (3,5), HC-3 was unable to antagonize antinociception induced by post-
synaptic muscarinic receptor agonists such as oxotremorine, McN-A-343, or AF-102B.
Moreover, PG-9 did not elicit the typical cholinergic symptoms (e.g., tremors, sialorrhea,
diarrhea, rhinorrhea, lacrimation) produced by directly acting postsynaptic muscarinic
agonists (8).
It is well known that the activation of the nicotinic system induces antinociception.
PG-9, even though it increases the extracellular levels of ACh, enhances the pain
threshold, an effect not prevented by mecamylamine. Thus, PG-9 does not act via nico-
tinic receptor-mediated mechanism of action. This hypothesis is supported also by the fact
that muscarinic antagonists do not prevent nicotinic antinociception at doses that antag-
onize muscarinic antinociception (29).
It has long been known that the activation of the cholinergic system induces antinoci-
ception (12,26,47–49,57,65) and facilitates cognitive processes (15). It is, therefore, con-
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ceivable that enhancement of extracellular levels of ACh may be considered responsible
for the antinociceptive effect of PG-9. Moreover, the PG-9-induced potentiation of endo-
genous ACh release may also counteract the amnesic effect produced by the antimuscari-
nic drugs scopolamine and dicyclomine.
ACh release can be increased by blocking M2M4 muscarinic autoreceptors
(55,59,73,71). The affinity profile of PG-9 versus M1 [rabbit vas deferens, according to
the methods of Eltze (23) as modified by Dei et al. (17)], M2 [guinea pig atrium, according
to the methods of Eltze et al. (21) modified by Dei et al. (17)], M3 [guinea pig ileum, ac-
cording to the methods of Eltze and Figala (22)] and putative M4 receptors [prepuberal
guinea pig uterus, according to the methods of Dörje et al. (19)] shows low M4M1 (11.2)
and M2M1 selectivity (8.3) ratios (Table 3). In this study the selectivity of PG-9 was com-
pared to that of the M4 antagonist R-(+)-hyoscyamine (30) and M2 antagonist AFDX-116
(38). It is possible that a low selectivity ratio of 11.2 may be high enough to enhance the
pain threshold and to reverse amnesia as a consequence of ACh release. The M2 muscari-
nic antagonists AFDX-116 (38), methoctramine (60), and AQRA-741 (18), as well as
PG-9, all of which have cholinergic presynaptic antinociceptive (4,28,42) and antiamnesic
(2) properties and are capable of increasing ACh release (55,73), have a selectivity ratio
M2M1 comparable to that of PG-9. Binding studies performed on the m1–m4 human
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Fig. 7. Dose-response curve of PG-9 on ACh release from parietal cortex. All values are expressed as changes
over basal output. PG-9 was administered at 60 min as shown by the arrow. Vertical lines give 
 S.E.M. Each
point represents the mean of at least 5 independent experiments. Doses of PG-9 are expressed as mgkg i.p. Sig-
nificant differences were evaluated by comparing the percentage variation vs. the mean 
 S.E.M. of all predrug
determinations. *P < 0.05 vs. controls.
muscarinic receptor subtypes expressed in CHO cells (11,20) confirm the results obtained
by functional studies (Table 3). It cannot be excluded, however, that other mechanisms ca-
pable of potentiating the endogenous cholinergic system may also be involved in the
antinociceptive and antiamnesic effects of PG-9.
It has been demonstrated that D2 dopaminergic (40,51,70,74), A1 adenosinergic
(10,52), H3 histaminergic (13), 5-HT4 serotoninergic heteroreceptors (14), and 5-HT1A re-
ceptors (7) increase ACh release. However, the above-mentioned receptors are not in-
volved in a PG-9 mechanism of action. In fact, PG-9 is able to interact with D2, H3,5-HT4,
and 5-HT1A receptors only at concentrations higher than 10–6 M as revealed by binding
studies (data not shown). These results are supported by the fact that quinpirole (D2 ag-
onist), N6-cyclopentyladenosine (A1 agonist), R-()-methylhistamine (H3 agonist),
GR-48125 (5-HT4 antagonist), and NAN 190 (5-HT1A antagonist), at doses able to
prevent the antinociception induced respectively by haloperidol (29), caffeine (34), thio-
peramide (58), BIMU 1 and BIMU 8 (32), and 5-HT1A agonists (25,31), failed to prevent
PG-9 antinociception (37).
Neurotransmitter systems, other than the cholinergic, are not involved in PG-9 antino-
ciception. At concentrations higher than 10–6 M this compound interacts with the fol-
lowing receptors, channels or receptor subtypes: 1, 2, 1, 2 adrenoceptors, D1,
GABAA, GABAB, H1, NK1, , ,  opioid, 5-HT1D, 5-HT2, 5-HT3, and K+ channels:
ATP-sensitive K+ channel, voltage-dependent K+ channel, and Ca2+-activated K+ channel.
The inability of the opioid antagonist naloxone, the GABAB antagonist CGP-35348, and
the biogenic amine depletor reserpine (37) to prevent PG-9 antinociception is in agree-
ment with the binding data. Pretreatment with pertussis toxin (PTX) prevented opioid
(63), catecholaminergic, GABAergic (50), histaminergic (24), and purinergic (69) anal-
gesia but not muscarinic antinociception (24). Since PG-9 antinociception was not pre-
vented by pretreatment with PTX (6), the hypothesis that a cholinergic mechanism un-
derlies the PG-9 activity is further supported.
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TABLE 3. Affinity profiles of PG-9, R-(+)-hyoscyamine and AFDX-116 at M1–M4 muscarinic
receptors and binding affinities of PG-9 and AFDX-116 for m1–m4 muscarinic receptor subtypes
expressed in Chinese hamster ovary cells (CHO-K1)
pA2 Values
M1 rabbit vas
deferens
M2 rat
left atrium
M3 rat
ileum
M4-putative
guinea-pig uterus
PG-9 6.69 
 0.04 6.81 
 0.09 6.86 
 0.10 7.74 
 0.05
R-(+)-hyoscyamine 7.05 
 0.05a 7.25 
 0.04a 6.88 
 0.05a 9.56 
 0.01a
AFDX-116 6.85 
 0.14b 7.12 
 0.11b 6.34 
 0.13c 6.70 
 0.06
pKi Values
m1 m2 m3 m4
PG-9 6.23 
 0.05d 6.31 
 0.06d 6.19 
 0.11d 7.10 
 0.09d
AFDX-116 6.84 
 10.14b 7.12 
 0.11b 6.34 
 0.13b 6.70 
 0.06
Each value represents the mean 
 S.E.M.; a ref. 30; b ref. 23; c ref. 22; d Ghelardini et al. Arzneimittel-
forschung 1999;49:483.
SUMMARY
PG-9 is a 2-arylpropionic acid ester, structurally related to atropine. It has central anti-
nociceptive and antiamnesic effects in mice and rats. These effects are exerted without im-
pairment of motor coordination and without typical cholinergic symptomatology. PG-9
potentiates evoked contractions of smooth and striated muscle. The mechanism of PG-9
action in the central and peripheral nervous systems appears to involve potentiation of en-
dogenous cholinergic activity and enhancement of extracellular ACh levels. Moreover, in
vitro administration of PG-9 increases secretion of NGF by astrocytes in a co-
ncentration-dependent manner.
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